newsAbbVie’s preventative migraine treatment atogepant (Qulipta™) shows promise16 March 2022 | By Mandy Parrett (European Pharmaceutical Review)AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.